NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied
Date of first enrollment	13/10/2017
Target sample size	1000
Countries of recruitment	Japan,North America,Europe
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : pembrolizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : pembrolizumab, docetaxel, oxaliplatin, 5-fluorouracil, leucovorin Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : cisplatin, capecitabine, 5-fluorouracil Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : docetaxel, oxaliplatin, 5-fluorouracil, leucovorin Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	safety efficacy
Secondary Outcome	safety efficacy

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria
Exclude criteria